News & Analysis as of

Biotechnology Private Equity

Cooley LLP

Driving Business Growth Through Investment Funds: Analyses and Practical Insights for Chinese Biotechs

Cooley LLP on

Over the past few years, we have been deeply engaged in – and have closely observed – the rapid growth of Chinese biotech companies. Despite a challenging market environment, these companies have continued to make remarkable...more

McDermott Will & Emery

Transaction and Financing Trends in Life Sciences - European Health & Life Sciences Symposium 2025

McDermott Will & Emery on

In April, McDermott was pleased to once again host our annual European Health & Life Sciences Symposium in Paris. Welcoming a crowd of more than 300 innovators, investors, business leaders and advisers from across the...more

Bennett Jones LLP

BBHIC 2025: Key Insights From Canada’s Leading Healthcare Investment Conference

Bennett Jones LLP on

The Bloom Burton & Co. Healthcare Investor Conference (BBHIC), held in Toronto this week, drew over 1,500 global participants to one of Canada's leading events for healthcare investment and innovation. The conference brought...more

Paul Hastings LLP

FDA Funding Changes Could Impact Biotech M&A

Paul Hastings LLP on

With companies constantly developing new therapies and technologies, the biotech industry is a hotbed of innovation. This dynamic environment often leads to mergers and acquisitions (M&A) as a vehicle for larger companies to...more

Mintz Edge

The State of the Funding Market for AI Companies: A 2024 - 2025 Outlook

Mintz Edge on

Artificial intelligence (AI) has emerged as an influential technology, driving notable investments across various industries in recent years. In 2024, venture capital (VC) funding for AI companies reached record levels,...more

Cooley LLP

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley LLP on

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% of New Year’s resolutions will have already failed by the end of the month....more

Davis Wright Tremaine LLP

Food Venture Financing News - Weekly Issue No. 219

Food Venture Financing Trends - Inari, a seed gene-editing company, raised $144 million in its Series G round....more

Foley Hoag LLP - Public Companies & the Law

Biotech Public Markets Finally Thawing(?): Two Massachusetts Biotechs file S-1s

In an encouraging sign that the equity capital markets may be improving for biotechnology companies, Bicara Therapeutics Inc. and Zenas Biopharma, Inc. filed S-1 registration statements yesterday, signaling their intention to...more

McDermott Will & Emery

Pharma and MedTech Services Investment Summit 2024

McDermott Will & Emery on

The inaugural Pharma and MedTech Services Investment Summit brought together C-suite executives, senior private equity professionals, investment bankers and other industry leaders for a deep dive into the investment...more

McDermott Will & Emery

[Event] Pharma and MedTech Services Investment Summit 2024 - May 2nd, San Francisco, CA

McDermott Will & Emery on

YOUR SOURCE FOR SUCCESS IN PHARMA AND DEVICE SERVICES INVESTING - Join C-suite executives, senior private equity professionals, investment bankers and other industry leaders for a deep dive into the investment...more

Troutman Pepper Locke

Ready for the Biotech Bounce Back in 2024?

Troutman Pepper Locke on

Heading into 2024, expectations for biotech venture capital (VC) and private equity (PE) investments were low following two lackluster years, but as we wrap up Q1, those expectations have been turned on their head after a...more

BakerHostetler

Healthcare Industry Team 2023 Year in Review

BakerHostetler on

As we approach the conclusion of another transformative year, we are excited to present our comprehensive year-end review, shedding light on the trends shaping the healthcare market in 2023. Our team’s keen insights and...more

White & Case LLP

Transatlantic M&A bull run set for comeback

White & Case LLP on

Encouraged by the relative strength of the dollar and improving financing conditions, US bidders are snapping up European assets - Transatlantic M&A was enjoying record-high activity before the war in Ukraine sparked...more

Hogan Lovells

Strategic financial options for clinical stage life sciences companies in a troubled equity market

Hogan Lovells on

Early 2023 has seen new and unprecedented financial challenges for clinical stage life sciences companies. The financing rounds of 2021 and 2022 are starting to run off, while at the same time the equity markets are either...more

White & Case LLP

Global healthcare M&A delivers strong performance

White & Case LLP on

Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in 2021, global healthcare M&A remained robust in 2022,...more

Hogan Lovells

JPM2023 Trendspotting: portfolio valuation in the aftermath of the IRA

Hogan Lovells on

As the industry readies itself for the January 2023 pilgrimage to the J.P. Morgan Healthcare Conference (JPM) and Biotech Showcase in San Francisco, our market-leading life sciences and health care industry team has prepared...more

Allen Matkins

Life Sciences Real Estate Update - September 2022

Allen Matkins on

Average sale price for U.S. life sciences properties hits record high Bullet Commercial Observer – August 17 According to a recent Newmark report, the national average sale price for a life sciences lab space reached a record...more

Gould + Ratner LLP

Ten Talks - Focus on Women Entrepreneurs - Conversation with Catherine Kleinmuntz

Gould + Ratner LLP on

In this first episode of our new series of video conversations focused on highlighting and showcasing women entrepreneurs in venture capital and private equity, Corporate Associate Ammara Khan talks with Principal of...more

White & Case LLP

Healthcare displays strong deal activity post-pandemic

White & Case LLP on

The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more

McDermott Will & Emery

What are the Life Science Transaction Trends in the Wake of the Sanitary Crisis?

McDermott Will & Emery on

In the second installment of McDermott’s webinar series, HPE Europe 2020: What are the Life Science Transaction Trends in the Wake of the Sanitary Crisis?, moderator and McDermott partner Emmanuelle Trombe and industry...more

Bass, Berry & Sims PLC

Key Takeaways from the Nashville Kayo Women in Healthcare and Finance Pop Up Discussion

Bass, Berry & Sims PLC on

Investors’ interest in healthcare continues to grow and healthcare-related deal flow in private equity appears to be at an all-time high. On November 5, Bass, Berry, & Sims member Tatjana Paterno moderated a Kayo Women in...more

Hogan Lovells

Life Sciences and Health Care Horizons - 2018

Hogan Lovells on

Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies were still in small-scale clinical...more

Hogan Lovells

A Chinese healthcare boom

Hogan Lovells on

Presenting a tremendous potential for growth fueled by domestic demographic and economic forces, China's healthcare industry has attracted notable PE investments in recent years. And with some commentators projecting that...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Scholar Rock Secures $36 Million in Funding

McGuireWoods LLP on

Scholar Rock, based in Cambridge, Mass., is a biotechnology company focused on developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment. The company’s initial drug...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Atreca Secures $56 Million in Funding

McGuireWoods LLP on

Atreca has announced it has secured $56 million in series A funding. Atreca, based in Redwood City, California, is a privately held biotechnology company developing therapeutics drawn from human immune responses,...more

28 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide